Carrie Smith Cox - Jun 4, 2021 Form 4 Insider Report for Organon & Co. (OGN)

Role
Director
Signature
/s/ Faye C. Brown, as Attorney-in-Fact for Carrie Smith Cox
Stock symbol
OGN
Transactions as of
Jun 4, 2021
Transactions value $
$651,748
Form type
4
Date filed
6/8/2021, 08:44 PM
Previous filing
Jun 2, 2021
Next filing
Nov 15, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Phantom Stock Award $652K +18.1K $36.05 18.1K Jun 4, 2021 Common Stock 18.1K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1-for-1
F2 Consists of (i) a one-time grant of 14,856 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.